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Introduction
Breast cancer is a major cause of death among women in
the United States and worldwide [1]. While cures are
probable if the cancer is detected early and remains local-
ized, many patients will succumb to the disease if the
primary tumor metastasizes to secondary organs.
Although significant progress has been made in detecting
and treating the primary tumor, the ability to predict the
metastatic behavior of a patient’s tumor and to eradicate
or control recurrent disseminated malignancy remain
major clinical challenges in oncology.
We have previously characterized an experimental system
that enables comparative molecular screening and func-
tional evaluation of candidate breast metastasis-related
genes in an isogenic background [2]. Two independent
clones of opposing metastatic phenotype were derived from
the MDA-MB-435 breast tumor cell line (metasatic M-4A4
FFPE = formalin-fixed, paraffin-embedded; H&E = hematoxylin and eosin; IHC = immunohistochemistry; LCM = laser capture microdissection; OPN =
osteopontin; PBS = phosphate-buffered saline; PCR = polymerase chain reaction; qPCR = real-time, quantitative PCR; RT = reverse transcriptase;
TSP-1 = thrombospondin-1; TYRP-1 = tyrosinase-related protein-1.
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Abstract
Background Our previous characterization of a human breast
tumor metastasis model identified several candidate
metastasis genes. The expression of osteopontin (OPN)
correlated with the metastatic phenotype, whereas
thrombospondin-1 (TSP-1) and tyrosinase-related protein-1
(TYRP-1) correlated with the nonmetastatic phenotype of
independent MDA-MB-435 cell lines implanted orthotopically
into athymic mice. The aim of the present study was to
examine the cellular distribution of these molecules in human
breast tissue and to determine whether the relative expression
level of these three genes is associated with human breast
tumor metastasis.
Methods  Sixty-eight fresh, frozen specimens including
31 primary infiltrating ductal carcinomas, 22 nodal metastases,
10 fibroadenomas, and five normal breast tissues were
evaluated for OPN expression, TSP-1 expression and TYRP-1
expression. Immunohistochemistry was performed to monitor
the cellular distribution and to qualitatively assess expression.
Quantitative analysis was achieved by enrichment of breast
epithelial cells using laser-capture microdissection and
subsequent real-time, quantitative PCR.
Results The epithelial components of the breast tissue were
the source of OPN and TSP-1 expression, whereas TYRP-1
was present in both the epithelial and stromal components.
Both OPN and TSP-1 expression were significantly higher in
malignant epithelial sources over normal and benign epithelial
sources, but no difference in expression levels was evident
between primary tumors with or without metastases, nor
between primary and metastatic carcinomas.
Conclusion Elevated expression of OPN and TSP-1 may play a
role in the pathogenesis of breast cancer. The multiplex
analysis of these molecules may enhance our ability to
diagnose and/or prognosticate human breast malignancy.
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and nonmetastatic NM-2C5 cell lines). When inoculated
into the mammary fat pad of athymic mice, both cell lines
form primary tumors. While clone M-4A4 aggressively
metastasizes to the lung and lymph nodes, the NM-2C5
clone is entirely nonmetastatic. Initial comparative gene
expression analysis of the two clones revealed the secreted,
integrin-binding protein osteopontin (OPN) [3] to be signifi-
cantly increased in the metastatic M-4A4 cell line. Con-
versely, the expression of thrombospondin-1 (TSP-1) [4]
and of tyrosinase-related protein-1 (TYRP-1) was markedly
overexpressed in the nonmetastatic NM-2C5 cell line [2,5].
OPN is a secreted glycophosphoprotein expressed by a
number of cell types, including leukocytes and epithelial
lineages, and it has been implicated biologically in bone
development, in immune system regulation [6], and in mul-
tiple mechanisms through signal transduction via its
binding to integrins [7]. OPN has been detected in
primary breast tumors and is elevated in the plasma of
patients with metastatic breast cancer [8,9], but an asso-
ciation between elevated levels of primary tumor OPN and
metastatic burden has not been well established.
TSP-1 is a homotrimeric multidomain glycoprotein synthe-
sized and secreted by numerous cell types, including
platelets, vascular smooth muscle cells and keratinocytes
[4]. Due to its interaction with a wide variety of proteins,
TSP-1 has been implicated in a number of biological
processes including coagulation, cell adhesion, the modu-
lation of cell–cell and cell–matrix interactions, control of
tumor growth and metastasis, and angiogenesis [10]. Inhi-
bition of tumor cell proliferation has been achieved in vivo
by systemic treatment with TSP-1 peptide mimetics [11],
but a correlation between primary tumor TSP-1 expression
and poor prognosis has not been clearly established [12].
While there are reports that these molecules can originate
from tumor cells [13], the majority of reports have sug-
gested that the major source of both TSP-1 and OPN is
tumor-associated stroma [14] or infiltrating macrophages
and lymphocytes [15].
The melanogenic enzymes TYRP-1 and TYRP-2 are well-
characterized differentiation antigens recognized by anti-
bodies and T cells of patients with melanoma [16]. The
evaluation of TYRP-1 expression in human breast lesions
has not been documented to date.
The aim of the present work was to examine the cellular
distribution of OPN, of TSP-1 and of TYRP-1 in human
breast tissue, and to determine whether the relative
expression level of these three genes was associated with
malignancy or breast tumor metastasis. To overcome the
problem of heterogeneity and stromal cell contamination in
homogenized tissue specimens, specific cell types were
isolated by laser capture microdissection (LCM) prior to
analysis. We used a combination of immunohistochemistry
(IHC), LCM and real-time, quantitative PCR (qPCR) analy-
sis of material obtained from a panel of primary breast infil-
trating ductal carcinomas and nodal metastases, and
compared the target gene expression levels with those
found in nonmalignant diseased tissue and in samples of
normal breast tissue.
Materials and methods
Tissue samples
Sixty-eight frozen human breast tissue specimens were
evaluated by LCM, qPCR and IHC, including 31 primary
tumors of infiltrating ductal carcinomas (22 primary tumors
with metastasis and nine primary tumors without known
metastasis), 22 matched nodal metastases, 10 fibro-
adenomas and five normal breast tissues (obtained from
reduction mammoplasty). In addition, eight tumor-associ-
ated stromal components (including fibroblasts, endothe-
lial cells and inflammatory cells) were microdissected from
primary tumors without known metastases for analysis.
Breast tissues were obtained from surgical specimens at
the John Radcliffe Hospital, Oxford, UK and at the UCSD
Medical Center. Samples were obtained in random order
from the residue of tissue used for pathological diagnosis
that would otherwise have been discarded. Tissues were
snap-frozen immediately after resection and were stored in
liquid nitrogen until analysis. Four pairs of additional forma-
lin-fixed, paraffin-embedded (FFPE) specimens of primary
infiltrating ductal carcinomas and of matched nodal metas-
tasis were also used for IHC only (total of 76 samples for
IHC). Histological diagnosis of all samples was performed
using H&E-stained cryostat sections (JWR). The histologi-
cal grade was assigned according to the modified
Bloom–Richardson grading scheme [17]. Tissue samples
were obtained and processed under approval of the
UCSD Institutional Review Board for studying existing
tissues (#011246X).
Laser capture microdissection
The total number of samples studied using LCM and
qPCR were 76 (68 samples were microdissected to
specifically enrich for cells of epithelial origin, and eight
samples were microdissected to obtain tumor-associated
stroma). Frozen tissues were embedded in Optimal
Cutting Temperature Compound (OCT; Sakura Finetek,
Torrance, CA, USA) and held at –70°C prior to sectioning.
Five-micrometer cryosections were mounted onto
uncoated microscope slides, immediately fixed by immer-
sion in acetone for 30s and washed with RNAse-free
water. Staining with H&E (Sigma, St Louis, MO, USA) for
1 min was performed for morphological evaluation. After
dehydration in 95% ethanol twice for 1 min and in 100%
ethanol for 1 min, sections were cleared in xylene for 2 min
and were air-dried. LCM was performed with the PixCell I
LCM System (Arcturus Engineering, Mountain View, CA,
USA). Following the manufacturer’s protocols, approxi-Breast Cancer Research    Vol 5 No 5 Wang-Rodriguez et al.
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mately 2–5000 cell equivalents were dissected from each
slide for subsequent analysis.
RNA extraction and cDNA synthesis
Total RNA was extracted from frozen breast tissues and
laser-captured materials using the StrataPrep Total RNA
kit (Stratagene, La Jolla, CA, USA). All samples were
DNase-treated to remove contaminating DNA and the
yield was measured spectrophotometrically. Single-
stranded cDNA was synthesized from total RNA using
MMLV reverse transcriptase (Retroscript RT kit; Ambion,
Inc.,  Austin, TX, USA).
Real-time, quantitative PCR
Primer sets for OPN, TSP-1, TYRP-1 and glyceraldehyde-3-
phosphate-dehydrogenase (GAPDH, the housekeeping
gene) were designed using Primer Express Version 1.5 soft-
ware (Applied Biosystems, Foster City, CA, USA). The qPCR
was performed on an Applied Biosystems PRISM 7700
Sequence Detection System using SYBR Green® I chem-
istry. Sequence Detection Software version 1.7 was applied
to data collection and analyses (Applied Biosystems).
The optimal primer concentrations for the reference and
target genes in the final PCR reaction were determined, and
both dissociation curves (ABI Dissociation Curves version
1.0 software; Applied Biosystems, Foster City, CA, USA)
and agarose gel electrophoretic analyses were applied to
confirm the specificity of PCR products and to check for the
presence of primer–dimer formations in the absence of a
template. Nontemplate control PCR reactions were always
run in triplicate for every gene-specific reaction mix.
Standard curves (cycle threshold values versus template
concentration) were prepared for each target and for the
endogenous reference (GAPDH) using cDNA from MDA-
MB-435 breast cells as the calibrator. For each experimen-
tal sample, the amount of target and endogenous reference
were determined from the respective standard curves, and
then the target amount was divided by the endogenous ref-
erence amount to obtain a normalized target value. The
sequences of the PCR primer pairs used for each gene are
as follows: TYRP-1, 5′-GATGGCAGAGATGATCGGGA-3′
and 5′-AGAAATTGCCGTTGCAGTGAC-3′; TSP-1, 5′-
CAGCAGCCGCTTTTATGT-3′ and 5′-CCGAGTATCCCT-
GAGCCCTC-3′; OPN, 5′-TTGCAGCCTTCTCAGCCAA-
3′ and 5′-GGAGGCAAAAGCAAATCACTG-3′; and
GAPDH, 5′-CCACCCATGGCAAATTCC-3′ and 5′-
GGGATTTCCATTGATGACA-3′.
Immunohistochemistry
All tissue specimens (68 frozen samples and eight FFPE
samples) were evaluated immunohistochemically. Mono-
clonal antibodies to OPN, to TYRP-1 and to TSP-1 were
purchased commercially (OPN [1:100], Chemicon Interna-
tional, Inc., Temecula, CA, USA; TYRP-1 [1:80, clone G-17],
Santa Cruz Biotechnology, Inc., CA, USA; TSP-1 [1:320],
BD Transduction Laboratories, CA, USA). The TYRP-1 and
TSP-1 antibody reactions were optimized using the DAKO
LSAB plus kit (DAKO, Carpinteria, CA, USA) for both frozen
and FFPE sections. The monoclonal rat anti-human OPN
antibody was optimized using the secondary biotinylated
rabbit anti-rat antibody (1:600) and streptavidin/horseradish
peroxidase (1:400; DAKO). Primary tumors recovered from
nude mice inoculated with the M-4A4 and NM-2C5 MDA-
MB-435 clones [2] were used as positive controls.
Tumor specimen staining was scored as positive or nega-
tive. Positive staining was defined as >50% of the tumor
cells or the benign epithelial components examined having
distinct cytoplasmic staining. The four additional FFPE
archived ductal carcinomas and the matched nodal metas-
tases (n=8) were stained with the aforementioned anti-
bodies using the antigen retrieval method now described
to assess the utility of the antibodies on archived tissues.
Serial frozen sections were cut for IHC and for LCM/RT-
qPCR for concurrent analysis. For frozen tissues, 5µm
cryostat sections (Leica Microsystems, Heidelberger,
Germany) were briefly fixed in acetone. Primary antibodies
were incubated on slides for 1 hour. After several wash-
ings with PBS, secondary antibodies conjugated with
streptavidin/horseradish peroxidase were added for
30 min–1 hour. The sections were washed and stained
with 3,3′-diamino-benzidine (DAKO) for 5 min and were
then counterstained with Gills II hematoxylin (Biochemical
Sciences, Inc., Swedesboro, NJ, USA).
For FFPE tissues, 5µm sections were cut and placed on
3-aminopropyltriethoxysilane-coated slides. After deparaf-
finization, the endogenous peroxidase was removed by
H2O2. Antigen retrieval was performed by steam heating
for 75 min. After sections were cooled to room tempera-
ture, the background staining was reduced by incubation
of serum against specific secondary antibody. Slides were
incubated with primary antibodies for 1 hour. After washing
with deionized water and PBS three times, species-
specific secondary antibodies were added and the anti-
body complex was visualized by 3,3′-diaminobenzidine. The
nuclei were counterstained by Gill’s II hematoxylin.
Statistical analysis
All statistical analyses used GraphPad Prism (GraphPad
Software Inc., San Diego, CA, USA). Comparison of
numerical data was achieved using a two-tailed unpaired t
test. P<0.05 was considered significant.
Results
Immunohistochemical detection of OPN, TSP-1 and
TYRP-1 in human breast tissues
The efficacy and specificity of OPN, TSP-1 and TYRP-1
antibodies in IHC was tested by analysis of frozen tissuexenografts of known target gene expression [2,5]. Positive
cytoplasmic staining was detected with the OPN antibody
in nine of 26 (35%) primary breast carcinomas with nodal
metastases. A representative example is depicted in
Figure 1. Six of 26 (23%) metastatic tissue samples and
five of nine (56%) primary tumors without metastases
were OPN-positive. Incubation of fibroadenoma and
normal breast tissue specimens with the OPN antibody
also produced positive staining in the epithelial cells of
53% of nonmalignant cases (five fibroadenomas and three
normal breast tissues). OPN was also regularly observed
in tumor-infiltrating inflammatory cells and macrophages
(Fig.1). Although difficult to quantitate, a trend of OPN
localization towards the epithelial layer but not the myoep-
ithelial layer was observed in normal breast tissue (Fig.1).
Overall, the degree and intensity of OPN expression was
qualitatively equal in samples of adenomas, adenocarcino-
mas and nodal metastases from patients with dissemi-
nated disease. The majority of primary carcinomas (66%)
that were positive for OPN also had concurrent OPN-posi-
tive metastases.
IHC staining of breast tissue sections revealed intracyto-
plasmic staining of TSP-1 in six of 26 (19%) node-positive
primary carcinomas and in 10 of 26 (38%) metastases. In
this case, all positive primaries had positive associated
metastases, although some metastatic tumors with posi-
tive TSP-1 expression had negative TSP-1 stain in their
primary tumors. TSP-1 staining was positive in two of nine
primary carcinomas without metastases (22%). Very weak
staining was observed in fibroadenoma and normal
tissues, and no TSP-1 was detected in breast tissue
stromal components.
A high percentage of node-positive primary tumors (73%),
metastatic carcinomas (73% and 100% concordance
between primary tumor and associated metastasis,
respectively), primary carcinomas without metastases
(89%), benign breast specimens (70%) and normal (60%)
breast specimens were positive for TYRP-1 staining
(Fig.1). TYRP-1 staining was confined to the cytoplasm
and to the epithelial components of the tissue. The stain-
ing achieved with all three antibodies was relatively homo-
geneous across the tumor in positive cases, and no
qualitative differences in staining were apparent at the
invasive edge of the carcinomas. No correlation was found
between protein expression and tumor grade in the infil-
trating ductal carcinomas, and no consistent qualitative
differences were revealed between primary tissues with or
without associated metastases.
LCM and qPCR analysis of breast tissues
While providing information on the cellular distribution of
target gene expression, the technique of one-color chro-
mogenic IHC staining can result in highly variable data
across samples, and it relies on visual ‘scoring’ that is rela-
tively subjective. To obtain accurate, quantitative informa-
tion on target gene expression we employed qPCR tech-
nology. The selection of specific cell types from the
heterogeneous cellular composition of the tissue speci-
mens was attained by LCM. This procedure allowed OPN,
TSP-1 and TYRP-1 mRNA analysis in specific cells of inter-
est in each case, eliminating the contribution from normal
adjacent cells that could cause difficulties in interpretation.
The cells of interest in the majority of cases were those of
epithelial origin, but eight specimens were also used for
the isolation of tumor-associated stroma (fibroblast,
endothelial and inflammatory cells) for comparison. We
measured the expression levels of the OPN, TSP-1 and
TYRP-1 genes using a quantitative PCR assay (RT-
qPCR). This analysis, in line with the findings of the IHC
data, confirms that breast tumor cells themselves synthe-
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Figure 1
Immunohistochemical detection of osteopontin (OPN),
thrombospondin-1 (TSP-1) and tyrosinase-related protein-1 (TYRP-1)
in normal and breast tumor cells. (A) Negative control (100×), (B)
cytoplasmic OPN staining of the majority of tumor cells in selected
cases (the stroma fibroblasts and endothelial cells did not stain for
OPN) (200×), (C) TYRP-1 staining in normal breast duct epithelium
(staining is specific for the epithelium and not for the surrounding
stroma tissue) (100×), (D) TSP-1 stained only selected tumor cells
(brown signal) and not the majority of the tumor (100×), (E) OPN was
localized in normal breast duct epithelium but not in myoepithelial cells
(100×), and (F) TRYP-1 in breast tumor cells (200×).size OPN, TSP-1 and TYRP-1 (in addition to tumor-infil-
trating macrophages in the case of OPN). Normal and
nonmalignant breast epithelia and stromal elements
expressed reduced levels of OPN and TYRP-1 transcripts.
Figures 2–4 demonstrate the differential expression
pattern and the quantitative expression level of each of the
three genes in human breast tissues. Relative to the
GAPDH transcript levels, OPN expression was found to
be ~10-fold higher than TYRP-1 expression in all tissues
examined. TSP-1 expression was comparable with that of
TYRP-1 in malignant cells but was at the limit of detection
in normal and benign epithelia and stromal components.
OPN mRNA was found to be present in all microdissected
tissue samples examined. Significantly elevated (~5-fold)
levels of OPN transcripts were observed in cells of epithe-
lial origin dissected from primary carcinomas and associ-
ated metastases over nonmalignant cell sources. All
primary tumors combined (P=0.017) and all metastases
(P=0.0082) exhibited significantly elevated OPN expres-
sion compared with normal epithelia (Fig.2). However,
there was no difference in OPN expression between
primary carcinomas with metastases and those without
metastases. Nor was there a quantitative difference in
OPN expression between primary carcinomas and
matched metastases (Fig.2).
While trace amounts were detected due to the sensitivity
of PCR amplification, thrombospondin transcripts were
essentially absent from breast tissue epithelia obtained
from normal and benign specimens, and there were no
appreciable levels detected in stromal tissue components.
However, TSP-1 levels were significantly raised in malignant
tissue epithelial sources (Fig.3). TSP-1 levels were signifi-
cantly higher (~10-fold) in all primary tumors (P=0.0017)
and in all metastases (P=0.0001) over normal breast
epithelia. In line with the OPN patterns of expression, there
was no significant difference in TSP-1 levels between
Breast Cancer Research    Vol 5 No 5 Wang-Rodriguez et al.
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Figure 3
Real-time, quantitative PCR analysis of thrombospondin-1 (TSP-1)
transcripts in human breast tissue components. The levels of TSP-1
transcripts were significantly higher (a, b, c, P<0.05) in all primary
breast carcinomas, with and without metastases, than in normal breast
epithelia, in fibroadenomas and in associated stromal components.
Error bars indicate the standard error of the mean.
Figure 4
Real-time, quantitative PCR analysis of tyrosinase-related protein-1
(TYRP-1) transcripts in human breast tissue components. There were
no significant differences in TYRP-1 transcript levels observed
between primary breast carcinomas, with metastases or without
metastases, and normal breast epithelia, fibroadenomas and
associated stromal components. Error bars indicate the standard error
of the mean.
Figure 2
Quantitative analysis of osteopontin (OPN) transcripts in human breast
tissue components. Epithelial and stromal components were
microdissected from tissue sections and subjected to real-time,
quantitative PCR analysis. The levels of OPN transcripts were
significantly higher (a, b, c, P<0.05) in all primary breast carcinomas
(with and without metastases) than in normal breast epithelia, in
fibroadenomas and in associated stromal components. Error bars
indicate the standard error of the mean.primary tumors with or without metastases, nor between
primary carcinomas and associated metastases.
TYRP-1 expression was higher than that of TSP-1 but
lower than that of OPN (10-fold to 50-fold). While TYRP-1
transcripts could be detected in all tissues examined
(Fig.4), including malignant and nonmalignant sources,
there were no significant quantitative differences revealed
between the types of tissue.
Discussion
A greater understanding of the molecular mechanisms
involved in metastatic spread is needed to facilitate
advances in prognostic evaluation for individual patients,
and in the design of therapeutic interventions to inhibit the
process. In an effort to establish a methodological frame-
work for analysis of the molecules and the mechanisms
involved in this complex multistep process, we previously
developed a well-defined experimental system in which
the role of candidate genes can be screened and tested
[2]. By serial dilution cloning of the MDA-MB-435 tumor
cell line and screening by orthotopic implantation into the
mammary fat pad of athymic mice, we derived a pair of
breast tumor cell lines (M-4A4 and NM-2C5) that originate
from the same breast tumor, but that have diametrically
opposite metastatic capabilities. Through multiple molecu-
lar analyses we have identified and verified a number of
genes whose expression correlates with the metastatic
phenotype in this xenograft model. The expression of the
proteins TSP-1 and TYRP-1 were found to correlate with
the nonmetastatic phenotype, whereas OPN was signifi-
cantly elevated in the metastatic counterpart. These find-
ings prompted us to investigate the occurrence and
distribution of these molecules in human breast tissues.
The investigative approach was designed to detect and
quantify the three molecules in specific breast tissue com-
ponents, data that were not previously available.
Having detected all three proteins immunohistochemically
in normal, benign and malignant breast epithelia, the quan-
titation of OPN, TSP-1 and TYRP-1 mRNA was achieved
using LCM and qPCR. This technique allows for the accu-
rate procurement of cells from specific microscopic
regions of tissue sections, and therefore enables the mole-
cular genetic analysis of pure populations of malignant
breast cells in their native tissue environment [18]. This
technical advance helps one to avoid the variation and
subjectivity associated with IHC, and to overcome the limi-
tations of data interpretation caused by tissue heterogene-
ity and normal stromal cell contamination in homogenized
tissue specimens. Coupled with qPCR, LCM can reveal
significant differences in specific gene expression that are
not accessible with relatively insensitive IHC alone.
We have demonstrated that human breast epithelia can
themselves synthesize OPN and, to a lesser extent, TSP-1
and TYRP-1 in vivo, and that elevated OPN and TSP-1
levels are indicative of malignancy. Significant OPN
expression has been reported in a number of breast
epithelial cell lines [19,20], and so it is known that cells of
breast epithelial origin can synthesize OPN in certain con-
ditions. But it is possible that in vitro OPN expression is a
phenomenon of cell culture or that OPN-positive cells
have a selective growth advantage during extended
passage. Synthesis of OPN was also observed in infiltrat-
ing lymphocytes and macrophages, a factor that would
seriously compromise efforts to quantify OPN in homoge-
nized tissue specimens. Such analysis would highlight
tumors with a high level of infiltrating inflammatory cells
rather than evaluate the levels of the marker molecule(s) in
the proliferative epithelia of a lesion.
As observed in IHC, tumor-infiltrating inflammatory cells
were presumably the stromal source of OPN. Transcript
levels in normal and fibroadenoma epithelia were equal to
those found in isolated stroma, indicating that the scattered
infiltrating macrophages (not lymphocytes) have relatively
high OPN expression. The presence of inflammatory infiltra-
tion is a serious problem in the molecular analysis of tissue
samples if the tissue is homogenized prior to analysis. The
presence of OPN in inflammatory cells highlights the
advantage of microdissection in this analytical context.
High levels of OPN in breast tumor cell lines appear to corre-
late with a more aggressive in vivo phenotype [2,20]. Trans-
fection of OPN expression constructs into cells producing
noninvasive mammary epithelial tumors has been reported to
convert them to a malignant phenotype [8,21]. Furthermore,
transfection of antisense OPN constructs or OPN-targeting
ribozymes into transformed tumorigenic cells can result in
impaired anchorage-independent growth, as well as in dimin-
ished tumor-forming ability in vivo [22,23]. OPN is also typi-
cally overexpressed in human tumors, including breast
cancer [15,24]. However, the source of OPN in primary
breast tumors was originally thought to be infiltrating
macrophages rather than tumor cells themselves [15].
By applying in situ hybridization, Tuck and colleagues identi-
fied breast tumor cells as a source of OPN [13]. Using a
semiquantitative scoring system to evaluate immunohisto-
chemical staining, these investigators found a correlation
between OPN positivity (defined as >33% of tumor cells in a
section staining for OPN) in lymph node-negative primary
breast carcinomas and patient survival, suggesting that tumor
cells with elevated OPN levels may behave differently with
regard to disease progression [13]. Another recent study
showed immunohistochemically that while OPN protein is
expressed weakly in normal breast tissue, OPN is expressed
strongly (>50% tumor cell staining) in pregnant/lactating
tissue and in the majority (66%) of breast carcinomas. These
investigators also found that the presence of OPN on tumor
cells is correlated with patient demise [25].
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tant confirmation of breast tumor cell OPN synthesis
because IHC analysis does not rule out the possibility that
secreted proteins such as OPN and TSP-1 are
sequestered by the tumor cells from the local environment.
Experiments with cell lines show that tumor cells can bind
soluble OPN and can migrate towards an OPN concentra-
tion gradient [8,19]; sequestration from the extracellular
matrix in vivo is thus pertinent. In the present study, the
epithelial layer appeared to express more OPN than the
myoepithelial cells, suggesting some OPN accumulation
or induction via the myoepithelial layer or via stromal inter-
actions. Unfortunately, the resolution of LCM does not
enable the selection of epithelial cells from myoepithelial
cells and so we were unable to confirm this quantitatively.
The effect of TSP-1 expression on tumor growth and metas-
tasis has been examined in vivo by orthotopic inoculation of
TSP-1-overexpressing MDA-MB-435 cells. A dose-depen-
dent inhibition of spontaneous pulmonary metastases was
reported, but this was paralleled by an inhibition of primary
tumor growth [26]. TSP-1 has also been implicated in the
phenomenon of concomitant tumor resistance. This refers
to the ability of some large primary tumors to hold smaller,
distant tumors in check, preventing their progressive
growth. Volpert and colleagues demonstrated this phenom-
enon using tumors formed by the human fibrosarcoma line
HT1080 in nude mice, and obtained data indicating that it
was caused by secretion of TSP-1 by the primary tumor
[27]. Some of the properties attributed to TSP-1 are con-
flicting, however; TSP-1 can be both adhesive and anti-
adhesive in vitro, can stimulate or inhibit angiogenesis, and
can inhibit or enhance proteolytic enzyme activity. The com-
position of the matrix, the availability of cytokines and pro-
teases, and the expression of various receptors in a given
cellular environment might explain these opposing functions.
Our findings in the MDA-MB-435 metastasis model are in
agreement with TSP-1 playing a role in the reduction of
metastatic potential [2]. Clinically, TSP-1 expression is
inversely correlated with tumor grade and survival rate in a
number of cancers [28,29], most probably because of the
anti-angiogenic effect of TSP-1. A recent study confirms
this to be the case in breast cancer, where expression of
TSP-1 in stroma adjacent to ductal carcinoma in situ is
lost in cases with more aggressive histological features
[30]. There are also reports, however, that fibroblast
TSP-1 can induce matrix metalloproteinase-9 in breast
tumor cells and gastric cancer tumor cells, and this in turn
may lead to a more invasive phenotype [14,31]. In the
present study, TSP-1 was not expressed differentially in
the stroma of benign tissue specimens or malignant tissue
specimens, nor in the epithelial component of breast
tumors with or without metastases. The increased levels
observed in malignant breast epithelia suggest a shift in
the balance between the anti-angiogenic and pro-invasive
effects of TSP-1 during tumor progression. The precise
biological role of TSP-1 in human tumor progression
awaits more definitive study.
In the present study, TYRP-1 mRNA was present, but at
very low levels, in breast tumor tissue, in associated stroma
and in normal breast tissues. However, IHC reveals that
TYRP-1 protein staining is easily detectable in many
samples. The melanogenic enzymes tyrosinase, TYRP-1
and TYRP-2 are well-characterized differentiation antigens
recognized by antibodies and T cells of patients with
melanoma. TYRP-1 is a type I membrane protein expressed
by melanomas and normal melanocytes that was originally
characterized as an oxidase in the melanin biosynthetic
pathway. Clinically, TYRP-1 is thought to be important as a
melanoma antigen that is highly antigenic to cytotoxic
T cells, providing a potential target for melanoma vaccine
development [16]. TYRP-1 appears to be less expressed in
advanced primary lesions and metastases of human cuta-
neous melanoma and uveal melanoma [32]. Primary
melanoma samples express TYRP-1 transcripts at higher
levels than melanoma metastases [33], and IHC analysis of
malignant melanocytic lesions has shown that the invasive
cells of primary melanomas are TYRP-1-negative [34].
Our finding that TYRP-1 is also expressed in the poorly
metastatic or noninvasive cell lines NM-2C5 [2], T47D,
MCF7 and DU145 [5], which are derived from human
breast cancers and prostate tumors that are nonmetasta-
tic, indicates that this molecule is not exclusively
expressed in cells of the melanocytic lineage. It has long
been known that the sera of patients who suffer from
melanoma or mammary carcinoma show higher tyrosinase
activity than normal sera [35] but, to our knowledge, this is
the first report of TYRP-1 expression in human breast duct
epithelium. The biological function of and any clinical sig-
nificance of TYRP-1 expression in normal or malignant
breast carcinomas are presently unknown.
Conclusion
We have quantitatively analyzed transcripts of OPN, of
TSP-1 and of TYRP-1 in microdissected human breast
tissues. Elevated levels of OPN and TSP-1 expression in
primary and metastatic carcinomas suggest that these
genes may be necessary for, but not sufficient for, dissem-
ination. Tumor cells that synthesize matrix-associated
factors such as OPN and TSP-1 may increase their ability
to independently manipulate their surroundings, encourag-
ing invasion and migration. These studies suggest that the
quantitative analyses of OPN and/or TSP-1 may be clini-
cally useful in identifying malignant lesions over benign
lesions but they are not, as yet, promising markers for the
evaluation of primary tumors for metastatic propensity.
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